Literature DB >> 16410456

Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.

Dick C Chan1, Gerald F Watts, Minh N Nguyen, P Hugh R Barrett.   

Abstract

OBJECTIVE: We investigated the associations between plasma very-low-density lipoprotein (VLDL)-apolipoprotein (apo)C-III and apoA-V concentrations and the kinetics of VLDL-apoB-100 and VLDL triglycerides in 15 men. We also explored the relationship between these parameters of VLDL metabolism and VLDL-apoC-III kinetics. METHODS AND
RESULTS: ApoC-III, apoB, and triglyceride kinetics in VLDL were determined using stable isotopes and multicompartmental modeling to estimate production rate (PR) and fractional catabolic rate (FCR). Plasma VLDL-apoC-III concentration was significantly and inversely associated with the FCRs of VLDL triglycerides (r=-0.610) and VLDL-apoB (r=-0.791), and positively correlated with the PR of VLDL-apoC-III (r=0.842). However, apoA-V concentration was not significantly associated with any of the kinetic variables. There was a significant association (P<0.01) between the PRs of VLDL triglycerides and VLDL-apoB (r=0.641), and between the FCRs of VLDL triglycerides and VLDL-apoB (r=0.737). In multiple regression analysis, plasma VLDL-apoC-III concentration was a significant predictor of VLDL triglyceride FCR (beta-coefficient=-0.575) and VLDL-apoB FCR (beta-coefficient=-0.839).
CONCLUSIONS: Our findings suggest that increased VLDL-apoC-III concentrations resulting from an overproduction of VLDL-apoC-III are strongly associated with the delayed catabolism of triglycerides and apoB in VLDL. We also demonstrated that the kinetics of VLDL triglycerides and apoB are closely coupled. Our data do not support a role for plasma apoA-V in regulating VLDL kinetics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410456     DOI: 10.1161/01.ATV.0000203519.25116.54

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  24 in total

1.  Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.

Authors:  G M Dallinga-Thie; A van Tol; H Hattori; L C van Vark-van der Zee; H Jansen; E J G Sijbrands
Journal:  Diabetologia       Date:  2006-04-28       Impact factor: 10.122

2.  Intestinal basolateral lipid substrate transport is linked to chylomicron secretion and is regulated by apoC-III.

Authors:  Diana Li; Cayla N Rodia; Zania K Johnson; Minkyung Bae; Angelika Muter; Amy E Heussinger; Nicholas Tambini; Austin M Longo; Hongli Dong; Ji-Young Lee; Alison B Kohan
Journal:  J Lipid Res       Date:  2019-05-31       Impact factor: 5.922

3.  Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.

Authors:  Chunyu Zheng; Christina Khoo; Jeremy Furtado; Frank M Sacks
Journal:  Circulation       Date:  2010-04-05       Impact factor: 29.690

4.  A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.

Authors:  Sumeet A Khetarpal; Xuemei Zeng; John S Millar; Cecilia Vitali; Amritha Varshini Hanasoge Somasundara; Paolo Zanoni; James A Landro; Nicole Barucci; William J Zavadoski; Zhiyuan Sun; Hans de Haard; Ildikó V Toth; Gina M Peloso; Pradeep Natarajan; Marina Cuchel; Sissel Lund-Katz; Michael C Phillips; Alan R Tall; Sekar Kathiresan; Paul DaSilva-Jardine; Nathan A Yates; Daniel J Rader
Journal:  Nat Med       Date:  2017-08-21       Impact factor: 53.440

Review 5.  The role of hypertriglyceridemia in atherosclerosis.

Authors:  Ngoc-Anh Le; Mary F Walter
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

6.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.

Authors:  Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig
Journal:  J Lipid Res       Date:  2009-06-10       Impact factor: 5.922

7.  The ins (cell) and outs (plasma) of apolipoprotein A-V.

Authors:  Trudy M Forte; Xiao Shu; Robert O Ryan
Journal:  J Lipid Res       Date:  2008-12-02       Impact factor: 5.922

8.  Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions.

Authors:  Meenakshi Sundaram; Shumei Zhong; Maroun Bou Khalil; Philip H Links; Yang Zhao; Jahangir Iqbal; M Mahmood Hussain; Robin J Parks; Yuwei Wang; Zemin Yao
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

Review 9.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef
Journal:  J Clin Endocrinol Metab       Date:  2012-09       Impact factor: 5.958

10.  Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.

Authors:  Dick C Chan; Minh N Nguyen; Gerald F Watts; P Hugh R Barrett
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.